FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with advanced small cell lung cancer whose disease has progressed after two or more lines of prior therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
